Taysha Gene Therapies

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of $46.6M vs. $42.5M expected, and EPS of -$0.13 vs. -$0.12 expected. Zero revenue was reported following the expiration of the Astellas agreement, in line with expectations for this clinical-stage phase. R&D expenses surged to $38.6M, driven by BLA-enabling PPQ manufacturing and clinical trial acceleration, while the cash position remains strong at $455.4M following a $215.6M public offering in June.